RESUMEN
Three schemes of synthesis for pentapeptide Glp-Glu-Asp-Cys-Lys-OH were compared was carried out. Acetamidomethyl protection was used for the mercapto group of cysteine. For the same purpose, cystine was used as the starting compound for synthesis. The optimal method was shown to be the solid phase method with S-acetamidomethyl cysteine protection that can be removed by mercuric acetate before the cleavage of a peptide from a polymer. The stabilized peptide inhibits proliferation of bone marrow cells of patients with chronic myeloleukemia 5- to 20-fold and has a less pronounced effect (up to 2-fold inhibition) on peripheral blood cells. Thus, its application for the therapy of hemoblastoses is promising.
Asunto(s)
Granulocitos/efectos de los fármacos , Hematopoyesis/efectos de los fármacos , Leucemia Mielógena Crónica BCR-ABL Positiva/patología , Oligopéptidos/farmacología , Secuencia de Aminoácidos , División Celular/efectos de los fármacos , Granulocitos/citología , Humanos , Datos de Secuencia Molecular , Oligopéptidos/síntesis química , Ácido Pirrolidona Carboxílico/análogos & derivados , Células Tumorales CultivadasRESUMEN
Radioimmunological examination of beta 2-microglobulin in the blood serum of 525 patients revealed that increased protein levels were observed in patients with malignant tumours of the pancreas, duodenal papilla, ovaries, soft tissues, lymphomas. In benign diseases (pancreatitis, ovarian cysts) the beta 2-microglobulin concentration did not significantly exceed the discrimination value. Due to the low sensitivity and specificity this protein has dubious significance as a tumour marker. It is suggested that in some cases of malignant tumours changes of the beta 2-microglobulin level may be related to hepatorenal insufficiency, spread of the disease. These data may provide supplementary information on the prognosis and evolution of the tumour process after combined treatment.